Keratoacanthoma
https://en.wikipedia.org/wiki/Keratoacanthoma
☆ Na nsonaazụ Stiftung Warentest nke 2022 sitere na Germany, afọ ojuju ndị ahịa na ModelDerm dị ntakịrị ntakịrị karịa na nyocha telemedicine akwụ ụgwọ. 

Ụdị Keratoacanthoma

Ikpe a nwere ọdịdị yiri wart.
relevance score : -100.0%
References
An Updated Review of the Therapeutic Management of Keratoacanthomas 36588786 NIH
Keratoacanthoma (KA) bụ akpụ akpụkpọ a na-ahụkarị maka uto ngwa ngwa yana ikike ịlaghachi azụ n'onwe ya. Ọ na-emekarị na ndị agadi nwoke nwere akpụkpọ ahụ mara mma nwere akụkọ ihe mere eme nke mmebi anyanwụ. Ọ bụ ezie na mwepụ ịwa ahụ site na iji mpụ ma ọ bụ ịwa ahụ micrographic Mohs bụ ọgwụgwọ a na-emebu, enwere nhọrọ ọgwụgwọ ndị ọzọ dị.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
A Clinical, Histopathological and Immunohistochemical Approach to the Bewildering Diagnosis of Keratoacanthoma 25191656 NIH
Keratoacanthoma (KA) bụ etuto dị obere nke na-amalite na ụfọdụ glands na akpụkpọ ahụ ma yie squamous cell carcinoma (SCC) n'okpuru microscope. Enwere arụmụka na-aga n'ihu gbasara ma a ga-ekewa KA dị ka ụdị SCC na-akpa ike.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Intralesional Treatments for Invasive Cutaneous Squamous Cell Carcinoma 38201585 NIH
Cutaneous squamous cell carcinoma (cSCC) bụ ụdị ọrịa kansa nke abụọ na-adịkarị na ndị mmadụ, ọkachasị n'etiti ndị agadi. A na-ejikarị ịwa ahụ na-agwọ cSCC, mana maka ụfọdụ ndị ọrịa na-enweghị ike ịwa ahụ ma ọ bụ họrọ ịghara, nhọrọ ndị ọzọ dị ka ọgwụgwọ intralesional nwere ike ịtụle. Ejila ọgwụgwọ intralesional ọdịnala (methotrexate or 5-fluorouracil) , mana enwere nyocha na-aga n'ihu na ụzọ ọhụrụ dị ka intralesional immunotherapy na oncolytic virotherapy. N'ebe a, anyị ga-eleba anya n'ọgwụgwọ intralesional dị iche iche maka cSCC, sitere na usoro kpochapụwo ruo na atụmatụ dị egwu.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
N'okpuru mikroskopu, keratoacanthoma yiri nnọọ carcinoma squamous cell. Ọ bụ ezie na ụfọdụ ndị ọkachamara n'ọrịa na-ekewa keratoacanthoma dị ka ihe dị iche na ọ bụghị ihe ọjọọ, ihe dị ka 6% nke ụlọ ọgwụ na histological keratoacanthoma na-enwe ọganihu na ọrịa cancer squamous cell na-emerụ ahụ.
○ Diagnosis na ọgwụgwọ
#Dermoscopy
#Skin biopsy